A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
The primary node molecules in the cell signaling network in cancer tissues are maladjusted and mutated in comparison to normal tissues, which promotes the occurrence and progression of cancer. Pancreatic cancer (PC) is a highly fatal cancer with increasing incidence and low five-year survival rates....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2024.1462808/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543766158082048 |
|---|---|
| author | Jinming Liu Biao Zhang Bingqian Huang Kexin Zhang Fujia Guo Zhizhou Wang Dong Shang Dong Shang |
| author_facet | Jinming Liu Biao Zhang Bingqian Huang Kexin Zhang Fujia Guo Zhizhou Wang Dong Shang Dong Shang |
| author_sort | Jinming Liu |
| collection | DOAJ |
| description | The primary node molecules in the cell signaling network in cancer tissues are maladjusted and mutated in comparison to normal tissues, which promotes the occurrence and progression of cancer. Pancreatic cancer (PC) is a highly fatal cancer with increasing incidence and low five-year survival rates. Currently, there are several therapies that target cell signaling networks in PC. However, PC is a “cold tumor” with a unique immunosuppressive tumor microenvironment (poor effector T cell infiltration, low antigen specificity), and targeting a single gene or pathway is basically ineffective in clinical practice. Targeted matrix therapy, targeted metabolic therapy, targeted mutant gene therapy, immunosuppressive therapy, cancer vaccines, and other emerging therapies have shown great therapeutic potential, but results have been disappointing. Therefore, we summarize the identified and potential drug-resistant cell signaling networks aimed at overcoming barriers to existing PC therapies. |
| format | Article |
| id | doaj-art-791a49b25455415585f50bb6206aa059 |
| institution | Kabale University |
| issn | 2296-634X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj-art-791a49b25455415585f50bb6206aa0592025-01-13T06:11:01ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-01-011210.3389/fcell.2024.14628081462808A stumbling block in pancreatic cancer treatment: drug resistance signaling networksJinming Liu0Biao Zhang1Bingqian Huang2Kexin Zhang3Fujia Guo4Zhizhou Wang5Dong Shang6Dong Shang7Department of General Surgery, Pancreas and Biliary Center, The First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of General Surgery, Pancreas and Biliary Center, The First Affiliated Hospital of Dalian Medical University, Dalian, ChinaKey Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Clinical Pharmacy, Affiliated Hangzhou First People’s Hospital, Westlake University, Hangzhou, ChinaCentral Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian, ChinaCentral Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of General Surgery, Pancreas and Biliary Center, The First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of General Surgery, Pancreas and Biliary Center, The First Affiliated Hospital of Dalian Medical University, Dalian, ChinaInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, ChinaThe primary node molecules in the cell signaling network in cancer tissues are maladjusted and mutated in comparison to normal tissues, which promotes the occurrence and progression of cancer. Pancreatic cancer (PC) is a highly fatal cancer with increasing incidence and low five-year survival rates. Currently, there are several therapies that target cell signaling networks in PC. However, PC is a “cold tumor” with a unique immunosuppressive tumor microenvironment (poor effector T cell infiltration, low antigen specificity), and targeting a single gene or pathway is basically ineffective in clinical practice. Targeted matrix therapy, targeted metabolic therapy, targeted mutant gene therapy, immunosuppressive therapy, cancer vaccines, and other emerging therapies have shown great therapeutic potential, but results have been disappointing. Therefore, we summarize the identified and potential drug-resistant cell signaling networks aimed at overcoming barriers to existing PC therapies.https://www.frontiersin.org/articles/10.3389/fcell.2024.1462808/fullpancreatic cancersignaling networkdrug resistancematrixgemcitabine |
| spellingShingle | Jinming Liu Biao Zhang Bingqian Huang Kexin Zhang Fujia Guo Zhizhou Wang Dong Shang Dong Shang A stumbling block in pancreatic cancer treatment: drug resistance signaling networks Frontiers in Cell and Developmental Biology pancreatic cancer signaling network drug resistance matrix gemcitabine |
| title | A stumbling block in pancreatic cancer treatment: drug resistance signaling networks |
| title_full | A stumbling block in pancreatic cancer treatment: drug resistance signaling networks |
| title_fullStr | A stumbling block in pancreatic cancer treatment: drug resistance signaling networks |
| title_full_unstemmed | A stumbling block in pancreatic cancer treatment: drug resistance signaling networks |
| title_short | A stumbling block in pancreatic cancer treatment: drug resistance signaling networks |
| title_sort | stumbling block in pancreatic cancer treatment drug resistance signaling networks |
| topic | pancreatic cancer signaling network drug resistance matrix gemcitabine |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2024.1462808/full |
| work_keys_str_mv | AT jinmingliu astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT biaozhang astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT bingqianhuang astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT kexinzhang astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT fujiaguo astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT zhizhouwang astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT dongshang astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT dongshang astumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT jinmingliu stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT biaozhang stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT bingqianhuang stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT kexinzhang stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT fujiaguo stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT zhizhouwang stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT dongshang stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks AT dongshang stumblingblockinpancreaticcancertreatmentdrugresistancesignalingnetworks |